TBC1 domain family member 29, pseudogeneGenealiases: []
Q-omics provides the consensus-scored TBC1D29P profile across patient tissues and cancer cell-line models. TBC1D29P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TBC1D29P is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, TBC1D29P RNA expression shows 16,356 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KICH, and UVM as cancer lineages where TBC1D29P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBC1D29P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBC1D29P survival associations across molecular data types. TBC1D29P RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBC1D29P RNA expression–survival associations across cancer types. High TBC1D29P expression shows unfavorable associations in KIRC, SCLC and COAD, but favorable associations in BLCA, SKCM and UCS. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify BLCA as the clearest survival context for TBC1D29P RNA expression.
This table summarizes TBC1D29P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TBC1D29P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBC1D29P shows lower tumor expression in KICH, THCA and BRCA and higher tumor expression in COAD, LUAD and HNSC. The KICH box plot shows higher TBC1D29P RNA expression in normal versus tumor tissue (log2 FC = −0.134, t-test p < 0.001).
This table shows molecular features associated with TBC1D29P in patient tissues and cancer cell lines. In patient samples, TBC1D29P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TBC1D29P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and STOMACH.
